Patients' and dermatologists' preferences in artificial intelligence-driven skin cancer diagnostics: A prospective multicentric survey study.

Competing Interests: Conflicts of interest Dr Utikal is on the advisory board or has received honoraria from Amgen, Bristol Myers Squibb, GSK, Immunocore, LeoPharma, Merck Sharp and Dohme, Novartis, Pierre Fabre, Roche, and Sanofi outside the submitted work. Dr Meier has received speaker's fees or/and advisor's honoraria from Novartis, Roche, BMS, MSD, and Pierre Fabre. Dr Hobelsberger reports speaker's honoraria from Almirall, UCB, and AbbVie. Dr Gellrich has received speaker's fees or/and advisor's honoraria by Sun Pharma, Sanofi, and Merck. Dr Hauschild reports speaker's honoraria or consultancy fees from the following companies: Agenus, Amgen, BMS, Dermagnostix, Highlight Therapeutics, Immunocore, Incyte, IO Biotech, MerckPfizer, MSD, NercaCare, Novartis, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme, Seagen, Sun Pharma, and Xenthera, outside the submitted work. Dr French is on the advisory board or has received consulting/speaker honoraria from for Galderma, Janssen, Leo Pharma, Eli Lilly, Almirall, Union Therapeutics, Regeneron, Novartis, Amgen, Abbvie, UCB, Biotest, and InflaRx. Dr Schlaak has received consultant or speaker fees or travel grants from BMS, MSD, Roche, Kyowa Kirin, Novartis, Sanofi Genzyme, Pierre Fabre, Sun Pharma, and Immunocore. Dr Erdmann declares honoraria from Bristol-Meyers Squibb, Immunocore, and Novartis outside the submitted work. Dr Haferkamp reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Novartis, Roche, BMS, Amgen, and MSD outside the submitted work. Dr Drexler has received honoraria from Pierre Fabre Pharmaceuticals and Novartis outside the submitted work. Dr Sondermann reports grants, speaker's honoraria, or consultancy fees from medi GmbH Bayreuth, Abbvie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, GSK, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi Genzyme, and UCB outside the submitted work. Dr Schilling reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Incyte, Novartis, Roche, BMS, and MSD. Dr Goebeler has received speaker's honoraria and/or has served as a consultant and/or member of advisory boards for Almirall, Argenx, Biotest, Eli Lilly, Janssen Cilag, Leo Pharma, Novartis, and UCB, outside the submitted work. Dr Kather reports consulting services for Owkin, France, Panakeia, UK, and DoMore Diagnostics, Norway and has received honoraria for lectures by MSD, Eisai, and Fresenius. Dr Brinker reports owning a company that develops mobile apps (Smart Health Heidelberg GmbH, Handschuhsheimer Landstr. 9/1, 69120 Heidelberg). Author Haggenmüller, Author Maron, Author Hekler, Dr Krieghoff-Henning, Dr Gaiser, Dr Müller, Dr Fabian, Dr Sergon, Dr Weichenthal, Dr Heinzerling, Dr Schlager, Dr Ghoreschi, Dr Hilke, Dr Pochi, Dr Korsing, Dr Berking, Dr Heppt, Dr Schadendorf, Dr Fröhling, Author Kaminski, Author Doppler, and Author Bucher have no conflicts of interest to declare.